IMCISION RNAseq

RNA sequencing could be performed on all 32 baseline and 30 on-treatment primary tumor biopsies. Based on gene-set enrichment analysis, the epithelial to mesenchymal transition signature was enriched in baseline tumors of patients without MPR, though its expression was insufficient to predict ICB response. Baseline and on-treatment IFNγ and T-cell signature expression (Z-score) were not significantly higher in patients with an MPR.­­­
Baseline primary tumor hypoxia-associated gene expression in IMCISION did not predict ICB response. However, on-treatment biopsies of MPR tumor samples showed significantly lower hypoxia gene expression when compared to non-MPR samples. Moreover, in a paired analysis of baseline and corresponding on-treatment samples, a significant decrease of hypoxia-related gene expression was observed in MPR biopsies, while this decrease was absent in non-MPR biopsies.EGA study EGAS00001005454

本数据集可对全部32份基线期与30份治疗期原发性肿瘤活检样本开展RNA测序（RNA sequencing）。基于基因集富集分析（gene-set enrichment analysis），上皮间质转化（epithelial to mesenchymal transition）特征在未获得主要病理缓解（major pathologic response, MPR）患者的基线期肿瘤中显著富集，但其表达水平不足以预测免疫检查点阻断（immune checkpoint blockade, ICB）治疗应答。基线期与治疗期的干扰素γ（IFN-γ）及T细胞特征表达（Z-score）在获得MPR的患者中未呈现显著升高。
IMCISION研究中，基线期原发性肿瘤缺氧相关基因表达无法预测ICB治疗应答。然而相较于非MPR样本，获得MPR的患者其治疗期肿瘤活检样本的缺氧基因表达水平显著更低。此外，针对基线期及对应治疗期样本的配对分析显示，MPR活检样本中缺氧相关基因表达出现显著下降，而非MPR活检样本则未观察到该变化。本数据集隶属于欧洲基因组表型档案（European Genome-phenome Archive, EGA）下的研究EGAS00001005454。